Bioregulator Research

Epitalon (Epithalon)

6.7/10

BioHarmony verdict

Worth trying

Epitalon is a synthetic AEDG tetrapeptide with in vitro telomerase and telomere data, animal lifespan signals, and Russian pineal-peptide melatonin studies. The score stays 6.5-7.0/10 because the strongest human claims are not independently replicated, and the 2025 Al-dulaimi paper adds mechanistic support plus cancer-cell ALT caution.

Read full report

What is Epitalon (Epithalon)?

Epitalon, also called Epithalon or AEDG, is a synthetic four-amino-acid peptide modeled after epithalamin, a pineal-gland peptide extract from the Russian bioregulator tradition. Its core claim is unusual: a short peptide cycle may influence telomerase, telomere length, melatonin rhythm, and age-related neuroendocrine decline. Khavinson 2003 reported telomerase activity and telomere elongation in cultured human somatic cells, while Al-dulaimi 2025 independently found telomere-length extension in normal epithelial and fibroblast cells and in breast-cancer cell lines.

From the BioHarmony report, reviewed 2026-09-08.

Safety watch-outs

  • Injection-site infection
  • New severe headache or neurological symptoms

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Epitalon (Epithalon) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (5)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established
Last checked2026-07-13
Next review2026-10-11

FDA identifies potential immunogenicity and peptide-impurity risks for compounded epitalon and says proposed-route safety information is insufficient.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.